Between 2000 and 2002, five class-action Ritalin lawsuits were filed in U.S. courts accusing Novartis Pharmaceuticals, the American Psychiatric Association, and the advocacy group Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) of conspiring to expand the ADHD diagnosis and drive prescriptions of methylphenidate. Every one of them was dismissed by a judge or voluntarily withdrawn by the plaintiffs. Separate individual injury suits and a recent federal enforcement action against a telehealth prescriber have since taken the place of the class-action strategy.
The Five Class Actions and What They Alleged
The named plaintiffs in all five cases were parents who had purchased Ritalin for their children and wanted their money back on behalf of a proposed class of similarly situated families. The theory tying the suits together was the same: Novartis (formerly Ciba-Geigy), the APA, and CHADD had run a decades-long conspiracy to broaden the market for methylphenidate.
Plaintiffs alleged that the APA had defined ADHD in the Diagnostic and Statistical Manual of Mental Disorders in an “overly broad manner” as part of an arrangement with Novartis to increase prescriptions. CHADD, they argued, functioned as a marketing conduit disguised as a grassroots patient organization, receiving money from Novartis in exchange for promoting Ritalin. The complaints also faulted Novartis for promotional materials that they said failed to disclose cardiovascular, central nervous system, gastrointestinal, and pituitary side effects of the drug.
The CHADD funding allegation had a documented basis. A mid-1990s television documentary revealed that Ciba-Geigy had given CHADD nearly $900,000 over five years without disclosure to most members, and a 1995 Drug Enforcement Administration background paper put contributions at over $775,000 by 1994, eventually exceeding $1 million. The United Nations International Narcotics Control Board accused CHADD of acting as “a vehicle for marketing a controlled substance directly to the public.”1PBS Frontline. Business of ADHD
The defendants rejected the conspiracy claims. Novartis called them “unfounded and preposterous” and described its grants to CHADD as “unrestricted educational grants.” The APA called the suits “ludicrous” and an “opportunistic attack on the scientific process.” CHADD compared the allegations to accusing the American Diabetes Association of conspiring with insulin manufacturers to invent diabetes.2PBS Frontline. Ritalin Lawsuits
Where and When Each Case Was Filed
The first suit was filed on May 1, 2000, in Cameron County, Texas, by attorney Andy Waters of the Dallas firm Waters & Kraus. Waters reportedly brought the case after reading psychiatrist Peter Breggin’s book Talking Back to Ritalin, and his firm operated the website RitalinFraud.com. The case was later transferred to federal court in Dallas.
Four more followed:
- Vess v. Ciba-Geigy Corp., filed September 13, 2000, in the U.S. District Court for the Southern District of California on behalf of minor Todd D. Vess and his guardian Deborah Vess, with Donald F. Hildre of Dougherty Hildre Dudek & Haklar as plaintiffs’ counsel.
- Dawson v. Ciba-Geigy, filed September 13, 2000, in Bergen County Superior Court in New Jersey.
- A Florida case filed in November 2000 in federal court in Orlando, with plaintiffs including a local mother and a couple from Puerto Rico.
- A Puerto Rico case filed in February 2001 in the U.S. District Court of Puerto Rico by San Juan attorney Peter Porrata.
How Each Case Ended
None of the five suits survived. The California case fell first. On March 8, 2001, U.S. District Judge Rudi Brewster dismissed Vess v. Ciba-Geigy, ruling that the complaint lacked “any allegations of causation, actional conduct, or damage” and that the defendants’ activities promoting ADHD diagnosis and treatment were protected speech under California’s anti-SLAPP statute.2PBS Frontline. Ritalin Lawsuits
The Texas case was dismissed after a judge found that the plaintiffs had failed to allege sufficient facts to constitute fraud or conspiracy. Both the Florida and Puerto Rico suits were voluntarily withdrawn by the plaintiffs before any judicial ruling, with the Puerto Rico withdrawal coming while dismissal motions were still pending.3Psychiatric News. APA Targeted in Five Ritalin Class-Action Suits
The New Jersey case lasted longest. Judge Charles Walsh ruled the claims “insufficiently specific” and gave the plaintiffs 90 days to provide additional evidence. They did not, and the case was withdrawn on February 5, 2002.4Psychiatric News. Last Ritalin Class Action Dismissed
The Ninth Circuit Appeal in Vess
The California plaintiffs appealed, and their case reached the U.S. Court of Appeals for the Ninth Circuit as Vess v. Ciba-Geigy Corp. USA, 317 F.3d 1097 (9th Cir. 2003). A panel of Circuit Judges Kim McLane Wardlaw and William A. Fletcher and District Judge Ronald M. Whyte issued its decision on January 31, 2003.5FindLaw. Vess v. Ciba-Geigy Corp. USA
The panel affirmed dismissal of all claims against the APA and CHADD, finding that those claims were “grounded in fraud” but lacked the specific “who, what, when, where, and how” required by Federal Rule of Civil Procedure 9(b). The court also upheld the use of California’s anti-SLAPP statute in federal court.6Leagle. Vess v. Ciba-Geigy Corp. USA
The appeals court did reverse dismissal of some claims against Novartis, holding that the lower court had improperly applied the heightened fraud-pleading standard to allegations that were not entirely based on fraud, and remanded those claims for further proceedings.5FindLaw. Vess v. Ciba-Geigy Corp. USA The decision is now frequently cited on the distinction between fraud-based and non-fraud-based claims in mixed complaints.7vLex. Vess v. Ciba-Geigy Corp. USA
Earlier Ritalin Lawsuits in the 1980s and 1990s
The 2000-era class actions were not the first courtroom challenge to Ritalin. A wave of suits in the late 1980s and early 1990s coincided with a campaign against ADHD medication led by the Citizens Commission on Human Rights, an anti-psychiatry organization founded by the Church of Scientology in 1969.8PubMed Central. Scientology and Psychiatry
In November 1987, LaVarne Parker filed a $125 million class action against the Gwinnett County School Board in suburban Atlanta and the American Psychiatric Association, alleging that her son had been medicated with Ritalin at the school’s insistence and that physicians had failed to warn parents about side effects. Her attorney was Washington, D.C., lawyer John P. Coale, and the CCHR was described as “instrumental in publicizing the issue.”9Christian Science Monitor. Ritalin Lawsuits The case was dismissed in 1988.2PBS Frontline. Ritalin Lawsuits
Around the same time, Adelia Lorenzo sued the Glendale Unified School District in California for $5 million, alleging her 11-year-old son had been coerced into taking Ritalin for three months, causing depression, headaches, and appetite loss. She was represented by Kendrick L. Moxon and Robert Brennan, both Scientologists, after being referred to Moxon by CCHR officials. The case went to trial in December 1990, but Judge Joseph Kalin declared a mistrial on the fourth day after witnesses introduced allegations of racism that the judge had previously excluded.10Los Angeles Times. The Legal Wrangle Over Ritalin The Los Angeles Times called it the “first attempt to recover damages from school districts over the administration of Ritalin.”
Individual Injury and Wrongful Death Cases
Individual families have pursued their own claims outside the class-action framework. In 2009, Edward and Susan Hill of Overland Park, Kansas, sued Ortho-McNeil-Janssen, Johnson & Johnson, and Novartis, alleging that their son Nicholas died in 2007 from methylphenidate toxicity after being prescribed both Ritalin and Concerta at the same time. Both drugs contain the same active ingredient, and the parents said the manufacturers failed to warn that the combination could be fatal. The complaint sought punitive damages for product liability, negligence, breach of warranty, and wrongful death.11Courthouse News Service. ADHD Drugs Killed Their Son, Parents Say
Separately, families have sued Janssen Pharmaceuticals over Concerta, alleging suicidal thoughts, suicide attempts, and self-injurious behavior. FDA data from 2006 documented 121 adverse event reports involving Concerta, with over a third involving children aged 10 or younger and most occurring in patients with no prior history of suicidal behavior. Health Canada began requiring stronger suicide-risk warnings on ADHD drug labels in 2015; the FDA has not added a comparable requirement to Concerta labeling in the United States.12Davis, Saperstein & Salomon. Concerta Suicidal Thoughts and Behavior Concerta is a related methylphenidate product, not Ritalin itself.
Recent Federal Enforcement: The Cerebral Settlement
The most recent significant action involving stimulant prescribing has come through federal enforcement rather than private litigation, and it targeted prescribing practices rather than the drug itself. In November 2024, the telehealth company Cerebral entered into a non-prosecution agreement with the U.S. Attorney’s Office for the Eastern District of New York, resolving an investigation into business practices between 2019 and 2022. Federal regulators alleged that Cerebral tracked stimulant prescription rates as performance metrics, pressured providers to hit prescribing targets for Adderall and other controlled substances, and maintained thousands of duplicate patient accounts to inflate its numbers.13U.S. Department of Justice. Telehealth Company Cerebral Agrees to Pay Over $3.6 Million
Under the agreement, Cerebral forfeited $3.65 million and faced an additional $2.92 million penalty that was deferred due to the company’s financial condition. Cerebral had already stopped prescribing all controlled substances in October 2022 and terminated its former CEO. The company also paid over $7 million in spring 2024 to settle Federal Trade Commission allegations that it had disclosed patient health information for advertising purposes and misled customers about cancellation policies.14Healthcare Dive. Cerebral Controlled Substance Prescribing Fine